-
XW0H Lower GI
-
XW0H0 Open
-
XW0H00 Brexanolone
-
XW0H00 Spesolimab Monoclonal Antibody
-
XW0H01 Daratumumab and Hyaluronidase-fihj
-
XW0H01 Eladocagene exuparvovec
-
XW0H02 Bromelain-enriched Proteolytic Enzyme
-
XW0H02 Nerinitide
-
XW0H03 Durvalumab Antineoplastic
-
XW0H03 Maribavir Anti-infective
-
XW0H04 Teclistamab Antineoplastic
-
XW0H05 Mosunetuzumab Antineoplastic
-
XW0H05 Narsoplimab Monoclonal Antibody
-
XW0H06 Afamitresgene Autoleucel Immunotherapy
-
XW0H06 Lefamulin Anti-infective
-
XW0H06 Terlipressin
-
XW0H07 Coagulation Factor Xa, Inactivated
-
XW0H07 Tabelecleucel Immunotherapy
-
XW0H07 Trilaciclib
-
XW0H08 Lurbinectedin
-
XW0H08 Mineral-based Topical Hemostatic Agent
-
XW0H08 Treosulfan
-
XW0H08 Uridine Triacetate
-
XW0H09 Ceftolozane/Tazobactam Anti-infective
-
XW0H09 Inebilizumab-cdon
-
XW0H09 Satralizumab-mwge
-
XW0H0A Cefiderocol Anti-infective
-
XW0H0A Ciltacabtagene Autoleucel
-
XW0H0B Amivantamab Monoclonal Antibody
-
XW0H0B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0H0B Omadacycline Anti-infective
-
XW0H0C Eculizumab
-
XW0H0C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0H0D Atezolizumab Antineoplastic
-
XW0H0D Engineered Allogeneic Thymus Tissue
-
XW0H0E Etesevimab Monoclonal Antibody
-
XW0H0E Remdesivir Anti-infective
-
XW0H0F Bamlanivimab Monoclonal Antibody
-
XW0H0F Other New Technology Therapeutic Substance
-
XW0H0G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0H0G Plazomicin Anti-infective
-
XW0H0G REGN-COV2 Monoclonal Antibody
-
XW0H0G Sarilumab
-
XW0H0H Axicabtagene Ciloleucel Immunotherapy
-
XW0H0H Other New Technology Monoclonal Antibody
-
XW0H0H Synthetic Human Angiotensin II
-
XW0H0H Tocilizumab
-
XW0H0J Apalutamide Antineoplastic
-
XW0H0J Tisagenlecleucel Immunotherapy
-
XW0H0K Fosfomycin Anti-infective
-
XW0H0K Idecabtagene Vicleucel Immunotherapy
-
XW0H0K Leronlimab Monoclonal Antibody
-
XW0H0L CD24Fc Immunomodulator
-
XW0H0L Erdafitinib Antineoplastic
-
XW0H0L Lifileucel Immunotherapy
-
XW0H0M Baricitinib
-
XW0H0M Brexucabtagene Autoleucel Immunotherapy
-
XW0H0M Esketamine Hydrochloride
-
XW0H0N Lisocabtagene Maraleucel Immunotherapy
-
XW0H0N Meropenem-vaborbactam Anti-infective
-
XW0H0P Antibiotic-eluting Bone Void Filler
-
XW0H0Q Tagraxofusp-erzs Antineoplastic
-
XW0H0R Fostamatinib
-
XW0H0R Venetoclax Antineoplastic
-
XW0H0S COVID-19 Vaccine Dose 1
-
XW0H0S Iobenguane I-131 Antineoplastic
-
XW0H0T COVID-19 Vaccine Dose 2
-
XW0H0T Ruxolitinib
-
XW0H0U COVID-19 Vaccine
-
XW0H0U Imipenem-cilastatin-relebactam Anti-infective
-
XW0H0V COVID-19 Vaccine Dose 3
-
XW0H0V Gilteritinib Antineoplastic
-
XW0H0W Caplacizumab
-
XW0H0W COVID-19 Vaccine Booster
-
XW0H0X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0H0X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0H0Y Other New Technology Monoclonal Antibody
-
-
XW0H3 Percutaneous
-
XW0H30 Brexanolone
-
XW0H30 Spesolimab Monoclonal Antibody
-
XW0H31 Daratumumab and Hyaluronidase-fihj
-
XW0H31 Eladocagene exuparvovec
-
XW0H32 Bromelain-enriched Proteolytic Enzyme
-
XW0H32 Nerinitide
-
XW0H33 Durvalumab Antineoplastic
-
XW0H33 Maribavir Anti-infective
-
XW0H34 Teclistamab Antineoplastic
-
XW0H35 Mosunetuzumab Antineoplastic
-
XW0H35 Narsoplimab Monoclonal Antibody
-
XW0H36 Afamitresgene Autoleucel Immunotherapy
-
XW0H36 Lefamulin Anti-infective
-
XW0H36 Terlipressin
-
XW0H37 Coagulation Factor Xa, Inactivated
-
XW0H37 Tabelecleucel Immunotherapy
-
XW0H37 Trilaciclib
-
XW0H38 Lurbinectedin
-
XW0H38 Mineral-based Topical Hemostatic Agent
-
XW0H38 Treosulfan
-
XW0H38 Uridine Triacetate
-
XW0H39 Ceftolozane/Tazobactam Anti-infective
-
XW0H39 Inebilizumab-cdon
-
XW0H39 Satralizumab-mwge
-
XW0H3A Cefiderocol Anti-infective
-
XW0H3A Ciltacabtagene Autoleucel
-
XW0H3B Amivantamab Monoclonal Antibody
-
XW0H3B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0H3B Omadacycline Anti-infective
-
XW0H3C Eculizumab
-
XW0H3C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0H3D Atezolizumab Antineoplastic
-
XW0H3D Engineered Allogeneic Thymus Tissue
-
XW0H3E Etesevimab Monoclonal Antibody
-
XW0H3E Remdesivir Anti-infective
-
XW0H3F Bamlanivimab Monoclonal Antibody
-
XW0H3F Other New Technology Therapeutic Substance
-
XW0H3G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0H3G Plazomicin Anti-infective
-
XW0H3G REGN-COV2 Monoclonal Antibody
-
XW0H3G Sarilumab
-
XW0H3H Axicabtagene Ciloleucel Immunotherapy
-
XW0H3H Other New Technology Monoclonal Antibody
-
XW0H3H Synthetic Human Angiotensin II
-
XW0H3H Tocilizumab
-
XW0H3J Apalutamide Antineoplastic
-
XW0H3J Tisagenlecleucel Immunotherapy
-
XW0H3K Fosfomycin Anti-infective
-
XW0H3K Idecabtagene Vicleucel Immunotherapy
-
XW0H3K Leronlimab Monoclonal Antibody
-
XW0H3L CD24Fc Immunomodulator
-
XW0H3L Erdafitinib Antineoplastic
-
XW0H3L Lifileucel Immunotherapy
-
XW0H3M Baricitinib
-
XW0H3M Brexucabtagene Autoleucel Immunotherapy
-
XW0H3M Esketamine Hydrochloride
-
XW0H3N Lisocabtagene Maraleucel Immunotherapy
-
XW0H3N Meropenem-vaborbactam Anti-infective
-
XW0H3P Antibiotic-eluting Bone Void Filler
-
XW0H3Q Tagraxofusp-erzs Antineoplastic
-
XW0H3R Fostamatinib
-
XW0H3R Venetoclax Antineoplastic
-
XW0H3S COVID-19 Vaccine Dose 1
-
XW0H3S Iobenguane I-131 Antineoplastic
-
XW0H3T COVID-19 Vaccine Dose 2
-
XW0H3T Ruxolitinib
-
XW0H3U COVID-19 Vaccine
-
XW0H3U Imipenem-cilastatin-relebactam Anti-infective
-
XW0H3V COVID-19 Vaccine Dose 3
-
XW0H3V Gilteritinib Antineoplastic
-
XW0H3W Caplacizumab
-
XW0H3W COVID-19 Vaccine Booster
-
XW0H3X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0H3X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0H3Y Other New Technology Monoclonal Antibody
-
-
XW0H7 Via Natural or Artificial Opening
-
XW0H70 Brexanolone
-
XW0H70 Spesolimab Monoclonal Antibody
-
XW0H71 Daratumumab and Hyaluronidase-fihj
-
XW0H71 Eladocagene exuparvovec
-
XW0H72 Bromelain-enriched Proteolytic Enzyme
-
XW0H72 Nerinitide
-
XW0H73 Durvalumab Antineoplastic
-
XW0H738Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
-
-
XW0H73 Maribavir Anti-infective
-
XW0H738Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
-
-
XW0H74 Teclistamab Antineoplastic
-
XW0H75 Mosunetuzumab Antineoplastic
-
XW0H75 Narsoplimab Monoclonal Antibody
-
XW0H76 Afamitresgene Autoleucel Immunotherapy
-
XW0H76 Lefamulin Anti-infective
-
XW0H76 Terlipressin
-
XW0H77 Coagulation Factor Xa, Inactivated
-
XW0H77 Tabelecleucel Immunotherapy
-
XW0H77 Trilaciclib
-
XW0H78 Lurbinectedin
-
XW0H78 Mineral-based Topical Hemostatic Agent
-
XW0H78 Treosulfan
-
XW0H78 Uridine Triacetate
-
XW0H79 Ceftolozane/Tazobactam Anti-infective
-
XW0H79 Inebilizumab-cdon
-
XW0H79 Satralizumab-mwge
-
XW0H7A Cefiderocol Anti-infective
-
XW0H7A Ciltacabtagene Autoleucel
-
XW0H7B Amivantamab Monoclonal Antibody
-
XW0H7B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0H7B Omadacycline Anti-infective
-
XW0H7C Eculizumab
-
XW0H7C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0H7D Atezolizumab Antineoplastic
-
XW0H7D Engineered Allogeneic Thymus Tissue
-
XW0H7E Etesevimab Monoclonal Antibody
-
XW0H7E Remdesivir Anti-infective
-
XW0H7F Bamlanivimab Monoclonal Antibody
-
XW0H7F Other New Technology Therapeutic Substance
-
XW0H7G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0H7G Plazomicin Anti-infective
-
XW0H7G REGN-COV2 Monoclonal Antibody
-
XW0H7G Sarilumab
-
XW0H7H Axicabtagene Ciloleucel Immunotherapy
-
XW0H7H Other New Technology Monoclonal Antibody
-
XW0H7H Synthetic Human Angiotensin II
-
XW0H7H Tocilizumab
-
XW0H7J Apalutamide Antineoplastic
-
XW0H7J Tisagenlecleucel Immunotherapy
-
XW0H7K Fosfomycin Anti-infective
-
XW0H7K Idecabtagene Vicleucel Immunotherapy
-
XW0H7K Leronlimab Monoclonal Antibody
-
XW0H7L CD24Fc Immunomodulator
-
XW0H7L Erdafitinib Antineoplastic
-
XW0H7L Lifileucel Immunotherapy
-
XW0H7M Baricitinib
-
XW0H7M6Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
-
-
XW0H7M Brexucabtagene Autoleucel Immunotherapy
-
XW0H7M6Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
-
-
XW0H7M Esketamine Hydrochloride
-
XW0H7M6Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
-
-
XW0H7N Lisocabtagene Maraleucel Immunotherapy
-
XW0H7N Meropenem-vaborbactam Anti-infective
-
XW0H7P Antibiotic-eluting Bone Void Filler
-
XW0H7Q Tagraxofusp-erzs Antineoplastic
-
XW0H7R Fostamatinib
-
XW0H7R7Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7
-
-
XW0H7R Venetoclax Antineoplastic
-
XW0H7R7Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7
-
-
XW0H7S COVID-19 Vaccine Dose 1
-
XW0H7S Iobenguane I-131 Antineoplastic
-
XW0H7T COVID-19 Vaccine Dose 2
-
XW0H7T Ruxolitinib
-
XW0H7U COVID-19 Vaccine
-
XW0H7U Imipenem-cilastatin-relebactam Anti-infective
-
XW0H7V COVID-19 Vaccine Dose 3
-
XW0H7V Gilteritinib Antineoplastic
-
XW0H7W Caplacizumab
-
XW0H7W COVID-19 Vaccine Booster
-
XW0H7X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0H7X8Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
-
-
XW0H7X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0H7X8Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
-
-
XW0H7Y Other New Technology Monoclonal Antibody
-
-
XW0H8 Via Natural or Artificial Opening Endoscopic
-
XW0H80 Brexanolone
-
XW0H80 Spesolimab Monoclonal Antibody
-
XW0H81 Daratumumab and Hyaluronidase-fihj
-
XW0H81 Eladocagene exuparvovec
-
XW0H82 Bromelain-enriched Proteolytic Enzyme
-
XW0H82 Nerinitide
-
XW0H83 Durvalumab Antineoplastic
-
XW0H83 Maribavir Anti-infective
-
XW0H84 Teclistamab Antineoplastic
-
XW0H85 Mosunetuzumab Antineoplastic
-
XW0H85 Narsoplimab Monoclonal Antibody
-
XW0H86 Afamitresgene Autoleucel Immunotherapy
-
XW0H86 Lefamulin Anti-infective
-
XW0H86 Terlipressin
-
XW0H87 Coagulation Factor Xa, Inactivated
-
XW0H87 Tabelecleucel Immunotherapy
-
XW0H87 Trilaciclib
-
XW0H88 Lurbinectedin
-
XW0H886Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
-
-
XW0H88 Mineral-based Topical Hemostatic Agent
-
XW0H886Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
-
-
XW0H88 Treosulfan
-
XW0H886Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
-
-
XW0H88 Uridine Triacetate
-
XW0H886Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
-
-
XW0H89 Ceftolozane/Tazobactam Anti-infective
-
XW0H89 Inebilizumab-cdon
-
XW0H89 Satralizumab-mwge
-
XW0H8A Cefiderocol Anti-infective
-
XW0H8A Ciltacabtagene Autoleucel
-
XW0H8B Amivantamab Monoclonal Antibody
-
XW0H8B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0H8B Omadacycline Anti-infective
-
XW0H8C Eculizumab
-
XW0H8C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0H8D Atezolizumab Antineoplastic
-
XW0H8D Engineered Allogeneic Thymus Tissue
-
XW0H8E Etesevimab Monoclonal Antibody
-
XW0H8E Remdesivir Anti-infective
-
XW0H8F Bamlanivimab Monoclonal Antibody
-
XW0H8F Other New Technology Therapeutic Substance
-
XW0H8G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0H8G Plazomicin Anti-infective
-
XW0H8G REGN-COV2 Monoclonal Antibody
-
XW0H8G Sarilumab
-
XW0H8H Axicabtagene Ciloleucel Immunotherapy
-
XW0H8H Other New Technology Monoclonal Antibody
-
XW0H8H Synthetic Human Angiotensin II
-
XW0H8H Tocilizumab
-
XW0H8J Apalutamide Antineoplastic
-
XW0H8J Tisagenlecleucel Immunotherapy
-
XW0H8K Fosfomycin Anti-infective
-
XW0H8K Idecabtagene Vicleucel Immunotherapy
-
XW0H8K Leronlimab Monoclonal Antibody
-
XW0H8L CD24Fc Immunomodulator
-
XW0H8L Erdafitinib Antineoplastic
-
XW0H8L Lifileucel Immunotherapy
-
XW0H8M Baricitinib
-
XW0H8M Brexucabtagene Autoleucel Immunotherapy
-
XW0H8M Esketamine Hydrochloride
-
XW0H8N Lisocabtagene Maraleucel Immunotherapy
-
XW0H8N Meropenem-vaborbactam Anti-infective
-
XW0H8P Antibiotic-eluting Bone Void Filler
-
XW0H8Q Tagraxofusp-erzs Antineoplastic
-
XW0H8R Fostamatinib
-
XW0H8R Venetoclax Antineoplastic
-
XW0H8S COVID-19 Vaccine Dose 1
-
XW0H8S Iobenguane I-131 Antineoplastic
-
XW0H8T COVID-19 Vaccine Dose 2
-
XW0H8T Ruxolitinib
-
XW0H8U COVID-19 Vaccine
-
XW0H8U Imipenem-cilastatin-relebactam Anti-infective
-
XW0H8V COVID-19 Vaccine Dose 3
-
XW0H8V Gilteritinib Antineoplastic
-
XW0H8W Caplacizumab
-
XW0H8W COVID-19 Vaccine Booster
-
XW0H8X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0H8X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0H8Y Other New Technology Monoclonal Antibody
-
-
XW0HX External
-
XW0HX0 Brexanolone
-
XW0HX0 Spesolimab Monoclonal Antibody
-
XW0HX1 Daratumumab and Hyaluronidase-fihj
-
XW0HX1 Eladocagene exuparvovec
-
XW0HX2 Bromelain-enriched Proteolytic Enzyme
-
XW0HX2 Nerinitide
-
XW0HX3 Durvalumab Antineoplastic
-
XW0HX3 Maribavir Anti-infective
-
XW0HX4 Teclistamab Antineoplastic
-
XW0HX5 Mosunetuzumab Antineoplastic
-
XW0HX5 Narsoplimab Monoclonal Antibody
-
XW0HX6 Afamitresgene Autoleucel Immunotherapy
-
XW0HX6 Lefamulin Anti-infective
-
XW0HX6 Terlipressin
-
XW0HX7 Coagulation Factor Xa, Inactivated
-
XW0HX7 Tabelecleucel Immunotherapy
-
XW0HX7 Trilaciclib
-
XW0HX8 Lurbinectedin
-
XW0HX8 Mineral-based Topical Hemostatic Agent
-
XW0HX8 Treosulfan
-
XW0HX8 Uridine Triacetate
-
XW0HX9 Ceftolozane/Tazobactam Anti-infective
-
XW0HX9 Inebilizumab-cdon
-
XW0HX9 Satralizumab-mwge
-
XW0HXA Cefiderocol Anti-infective
-
XW0HXA Ciltacabtagene Autoleucel
-
XW0HXB Amivantamab Monoclonal Antibody
-
XW0HXB Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0HXB Omadacycline Anti-infective
-
XW0HXC Eculizumab
-
XW0HXC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0HXD Atezolizumab Antineoplastic
-
XW0HXD Engineered Allogeneic Thymus Tissue
-
XW0HXE Etesevimab Monoclonal Antibody
-
XW0HXE Remdesivir Anti-infective
-
XW0HXF Bamlanivimab Monoclonal Antibody
-
XW0HXF Other New Technology Therapeutic Substance
-
XW0HXG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0HXG Plazomicin Anti-infective
-
XW0HXG REGN-COV2 Monoclonal Antibody
-
XW0HXG Sarilumab
-
XW0HXH Axicabtagene Ciloleucel Immunotherapy
-
XW0HXH Other New Technology Monoclonal Antibody
-
XW0HXH Synthetic Human Angiotensin II
-
XW0HXH Tocilizumab
-
XW0HXJ Apalutamide Antineoplastic
-
XW0HXJ Tisagenlecleucel Immunotherapy
-
XW0HXK Fosfomycin Anti-infective
-
XW0HXK Idecabtagene Vicleucel Immunotherapy
-
XW0HXK Leronlimab Monoclonal Antibody
-
XW0HXL CD24Fc Immunomodulator
-
XW0HXL Erdafitinib Antineoplastic
-
XW0HXL Lifileucel Immunotherapy
-
XW0HXM Baricitinib
-
XW0HXM Brexucabtagene Autoleucel Immunotherapy
-
XW0HXM Esketamine Hydrochloride
-
XW0HXN Lisocabtagene Maraleucel Immunotherapy
-
XW0HXN Meropenem-vaborbactam Anti-infective
-
XW0HXP Antibiotic-eluting Bone Void Filler
-
XW0HXQ Tagraxofusp-erzs Antineoplastic
-
XW0HXR Fostamatinib
-
XW0HXR Venetoclax Antineoplastic
-
XW0HXS COVID-19 Vaccine Dose 1
-
XW0HXS Iobenguane I-131 Antineoplastic
-
XW0HXT COVID-19 Vaccine Dose 2
-
XW0HXT Ruxolitinib
-
XW0HXU COVID-19 Vaccine
-
XW0HXU Imipenem-cilastatin-relebactam Anti-infective
-
XW0HXV COVID-19 Vaccine Dose 3
-
XW0HXV Gilteritinib Antineoplastic
-
XW0HXW Caplacizumab
-
XW0HXW COVID-19 Vaccine Booster
-
XW0HXX Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0HXX Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0HXY Other New Technology Monoclonal Antibody
-
-